Automation

PRODUCTS

  • Power. Potential. Productivity.

    STELLARIS 5 is a completely re-imagined confocal microscope platform.

    STELLARIS confocal microscopes can be combined with all Leica modalities, including FLIM, STED, DLS, and CRS. With the STELLARIS confocal platform, we have re-imagined confocal microscopy to get you closer to the truth.

    • Power to see more
    • Potential to discover more
    • Productivity to do more
  • The Aclara RF Data Collection Unit’s (DCU2+) advanced design meets all the needs of electric, water, and gas utilities looking for an advanced communication backbone.

  • Every capsule and tablet begins with an idea. It takes a professional and innovative manufacturing partner to turn that idea into a reality. Enter Natoli, a name synonymous with excellence in pharmaceutical equipment and services. From the early stages of formulation to the grand scale of full-blown production, Natoli offers a seamless journey through every step of the process. Whether you’re unsure of how to start or how to finish, Natoli can guide the way.

  • Curia’s combined expertise and a proven track record of success in key scientific disciplines including molecular biology, protein production and analysis, enzymes, nucleosides and lipids is the foundation of our mRNA solution. Partner with us and harness our ability to provide high-quality constructs through in-house research and analysis capabilities that enable accelerated timelines for delivery.

  • Delivering on the promise of cell and gene therapy

    Germfree is a leader in creating mobile and modular facilities specifically for cell and gene therapy (CGT) manufacturing. As CGT sits at the crossroads of medical research and pharmaceutical development, it demands highly specialized cleanroom designs. These designs must focus on efficient workflows, strict separation procedures, and rigorous aseptic processing to ensure the best results. Despite the quick growth and logistical challenges in the CGT field, Germfree’s mobile solutions effectively tackle these issues. They enable distributed manufacturing, ease the collection of patient cells, and help make CGT treatments accessible globally.

WHITE PAPERS AND CASE STUDIES

NEWS